To The Moon

The scary number isn't the important one

Moderna is supposedly caught between collapsing COVID revenues and a $3 billion cash-burning machine. That makes a wonderfully dramatic investment thesis. It is also slightly misleading.

At $198.88, $Moderna, Inc.(MRNA)$ carries a market capitalisation of roughly $79.4 billion despite generating just $2.23 billion of trailing revenue. Investors are therefore paying approximately 35.6 times trailing sales for a company currently producing negative gross profit.

That is an extraordinary multiple. But Moderna is increasingly being valued neither as a vaccine manufacturer nor as a conventional loss-making biotech. The market is assigning substantial value to something harder to measure: whether its mRNA platform can repeatedly convert genetic information into commercially useful medicines.

The question is no longer whether Moderna survives its post-COVID hangover. It is whether tomorrow's medicines can possibly justify today's price.

The frightening number may be the least frightening part

Cash burn: follow the money, not the headline

Here is the first misconception worth killing.

Moderna's trailing net loss is $3.15 billion, but trailing operating cash outflow is $1.07 billion and free cash flow is negative $1.24 billion. Neither number deserves applause, but Moderna is not physically burning $3 billion of cash annually.

Its balance sheet remains substantial. At June 2026, Moderna held $5.14 billion of cash and short-term investments plus $1.77 billion of long-term investments, against $1.29 billion of debt.

More importantly, free cash flow has improved from negative $4.06 billion in 2024 to negative $2.07 billion in 2025 and negative $1.24 billion TTM. Capital expenditure has collapsed from $1.05 billion in 2024 to $171 million TTM.

The cash burn is shrinking faster than the headline suggests

< Insert CHART 1 Here > Caption: The cash burn is shrinking faster than the headline suggests

Management now expects $4.7–$5.2 billion of year-end cash and has lowered its 2026 operating-expense outlook.

The cash crisis, therefore, is not today's problem.

Valuation is.

Intismeran has crossed a serious line

The investment case changed materially in August.

Moderna and Merck's Phase 3 INTerpath-001 trial of personalised cancer therapy intismeran autogene plus Keytruda met both recurrence-free survival and distant-metastasis-free survival endpoints in high-risk melanoma.

That moves personalised mRNA oncology from fascinating experiment towards potentially commercial medicine.

But Moderna does not own this field.

BioNTech and Genentech are developing autogene cevumeran using a similar individualised neoantigen strategy. Their Phase 2 colorectal programme was terminated in August following a Data Safety Monitoring Board recommendation after disappointing efficacy developments, although a pancreatic cancer trial continues. Other neoantigen approaches are advancing too.

Intismeran therefore gives Moderna something valuable, but narrower than a monopoly: pivotal evidence that its approach works in melanoma and a potential first-mover advantage alongside Merck's formidable oncology franchise.

Competitors still have maps. Moderna has simply travelled further down the road.

Bespoke medicine meets the factory floor

This leads to the question investors should probably worry about more than AI.

Every intismeran patient requires tumour sequencing, identification of mutations, computational selection of neoantigens and manufacture of an individual mRNA therapy.

That is scientifically elegant. Economically, it is almost the opposite of manufacturing aspirin.

Traditional pharmaceuticals gain enormous leverage by producing millions of identical doses. Personalised cancer vaccines potentially require something closer to a miniature manufacturing cycle for every customer.

Moderna believes automation, common manufacturing architecture and algorithmic design can compress that complexity. If it succeeds, its platform becomes genuinely valuable industrial infrastructure.

But the crucial commercial variables — manufacturing cost per patient, turnaround time at scale, failure rates and eventual gross margin — remain insufficiently proven publicly.

That matters enormously when Moderna's current trailing gross margin is roughly negative 66%.

The real oncology breakthrough, therefore, will not merely be regulatory approval. It will be demonstrating that bespoke medicine can produce repeatable margins.

Even brilliant science eventually meets an accountant.

AI is an accelerator, not pixie dust

Moderna's computational systems can optimise mRNA sequences and, in personalised oncology, help select neoantigens from individual tumours.

That is genuine applied AI.

Yet the investment value of AI is not the algorithm itself. It lies in whether computation can shorten design cycles, improve candidate selection, reduce manufacturing complexity and ultimately lower the cost of producing successful medicines.

That distinction matters. An AI-enabled platform that repeatedly creates valuable drugs is a moat. An AI-enabled platform that repeatedly creates expensive experiments is simply a faster way to spend money.

Five products, one political weather system

Moderna now has five approved products following the August approval of influenza vaccine MFLUSIVA for people aged 50 and above.

Yet commercial execution remains awkward.

mRESVIA competes with GSK's Arexvy and Pfizer's Abrysvo. GSK's vaccine division generated £9.2 billion in 2025, including £600 million from Arexvy — roughly $12.4 billion and $810 million respectively at an illustrative £1=$1.35 conversion. $Moderna, Inc.(MRNA)$ is challenging companies with enormous distribution machinery and established payer relationships.

There is another risk that spreadsheets handle badly: Washington.

U.S. vaccine policy has undergone substantial institutional change since HHS replaced the 17 sitting ACIP members in 2025. Regulatory scrutiny and political debate around vaccination, particularly mRNA technology, create additional uncertainty around recommendations, reimbursement and public uptake.

Current CDC guidance still recommends RSV vaccination for eligible older and higher-risk adults without preferring one of the three available products. But for Moderna, regulatory approval does not automatically translate into demand.

The FDA can approve a vaccine. It cannot make someone roll up their sleeve.

The multiple is really an oncology wager

Comparing Moderna's price-to-sales multiple with mature Pfizer or GSK would be misleading because those companies possess huge established revenue bases. Comparing it with early-stage biotechnology companies is equally imperfect because Moderna already has five approved products and substantial commercial infrastructure.

That awkwardness is itself informative.

At approximately 35.6 times trailing sales and 33.1 times EV/sales, Moderna occupies a valuation no-man's-land: commercially established enough to be judged on revenue, yet valued largely on future pipeline economics.

BioNTech provides perhaps the closest conceptual comparator, but even that comparison is distorted by partnership revenues, differing oncology portfolios and balance sheets.

I therefore would not call 35.6 times sales expensive merely because the number looks enormous. I would call it demanding because current revenues contribute remarkably little mathematical support to an almost $80 billion equity valuation.

And Wall Street appears to have been overtaken by its own bull case. Argus's ostensibly bullish $180 target, Rothschild Redburn's $81 bearish target and the $119.56 analyst consensus all sit below Moderna's $198.88 share price. When even the bull target requires the shares to fall, the spreadsheet has developed a sense of humour.

The share price moved faster than the analysts could type

Investors are effectively capitalising future oncology success before its economics are visible.

Proving the medicine works was only half the experiment

The mirage has moved

I think the simplistic bear case is weakening.

The $3 billion annual cash-burn narrative confuses accounting losses with substantially lower actual free-cash-flow burn. Moderna's balance sheet still gives it time, cost reductions are working, five products are approved and Phase 3 intismeran has delivered genuine platform validation.

But the bull case now carries its own illusion.

Clinical success does not yet prove that personalised cancer vaccines can be manufactured at attractive margins, competitors have not disappeared, vaccine demand faces unusual political uncertainty and today's valuation already anticipates substantial future commercial success.

So the original mirage was seeing a $3 billion cash inferno that was not really there.

The new one would be assuming that because Moderna has proved the science can work, it has already proved the economics will.

It hasn't.

And at nearly $80 billion, that may now be the only mirage that matters.

@TigerStars @Daily_Discussion @Tiger_comments @Tiger_SG @Tiger_Earnings @TigerClub @TigerWire